Journey Medical Corp. (DERM)

Several events have impacted Journey Medical Corp.'s stock price in the past six months. The company reported an EPS of -$0.163 for Q2 2025 and an EPS of -$0.09 for Q3 2025, missing the consensus estimate. Total revenues increased by 21% year-over-year, driven by the successful U.S. commercial launch of Emrosi. Emrosi's successful launch and strong prescription growth have been highlighted as a significant positive. HC Wainwright initiated coverage with a "buy" rating and a $13.00 price objective, and Lake Street Capital raised its price objective from $9.00 to $13.00 with a "buy" rating. Zacks Research raised Journey Medical from a "strong sell" to a "hold" rating. Journey Medical was added to the Russell 2000® and Russell 3000® indexes at the end of June 2025.

The provided information does not explicitly detail the demand seasonality for Journey Medical Corp.'s products and services. Dermatological conditions can sometimes exhibit seasonal patterns, but without specific data from the company, it is difficult to definitively state the demand seasonality for their particular product portfolio.

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing pharmaceutical products for dermatological conditions in the United States. The company's product portfolio includes FDA-approved prescription drugs such as Qbrexza, Accutane, Amzeeq, Zilxi, Emrosi, Exelderm, Targadox, and Luxamend.

Journey Medical Corporation primarily focuses its commercialization efforts in the United States, covering approximately 80% of the top 50 Metropolitan Statistical Areas (MSAs) and providing access to about 70% of all dermatology prescriptions in its focus disease states. The company is exploring opportunities for geographic expansion beyond the United States, targeting international markets with high demand for dermatology treatments.

Information directly detailing Journey Medical Corp.'s brand reputation is not explicitly available. The company emphasizes its team of industry experts and the successful launch and growth of Emrosi, which likely contributes positively to its reputation. The publication of Emrosi's Phase 3 clinical trials and its inclusion in treatment algorithms also indicate a positive scientific and medical reputation for this product.

Journey Medical Corp. stock ownership is a mix of institutional shareholders, insiders, and retail investors. Approximately 31.54% to 40.76% of the company's stock is held by institutional investors. Insiders own approximately 19.72% to 31.12% of the company's stock. Retail investors hold approximately 37.33% to 39.53% of the stock.